Nirsevimab is named as a drug or biological intervention in 3 clinical trials in our China and India trial registers, 1 of which is recruiting. Lead sponsors include Shanghai Institute Of Biological Products (2) and Sanofi (1). Registered phases: Phase 4, Phase EARLY_PHASE1 and Phase 1/2. Conditions studied include Respiratory Syncytial Virus (RSV); RSV Immunization.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07106918 | A Clinical Trial of SIBP-A16 Injection in Healthy Adults (ClinicalTrials.gov ↗) Respiratory Syncytial Virus (RSV) |
Phase EARLY_PHASE1 | Recruiting |
| NCT07363837 | Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants (ClinicalTrials.gov ↗) Respiratory Syncytial Virus (RSV) |
Phase 1/2 | Not yet open |
| NCT07109297 | Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India RSV Immunization |
Phase 4 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Respiratory Syncytial Virus (RSV) | 2 |
| RSV Immunization | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Institute Of Biological Products | 2 |
| Sanofi | 1 |
| Register | Nirsevimab trials |
|---|---|
| Clinical trials in China | 2 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nirsevimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nirsevimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.